Biotech & Health

Gaithersburg’s AstraZeneca Reports Robust Data From COVID-19 Clinical Trial

MBS Staff

AstraZeneca is in the race to develop the first COVID-19 vaccine and today it showed that it’s widening the gap. The tier one biopharma is one of several companies with large operations in Montgomery County.

While its COVID-19 trial is being spearheaded at its headquarters in Europe, the company has its massive operations center for the U.S. in Gaithersburg including its primary biologics research and development arm as well as its Global Medicines Development function and Specialty Products Group.

The Oxford University led study showed robust immune responses from vaccinated patients infected with the SARS-CoV-2 virus. The trial demographic includes 1,077 healthy adult participants 18-55 years-old in age.

With a single dose for most patients, the injection of AstraZeneca AZD1222 vaccine resulted in a four-fold increase in antibodies after a month.

Late-stage Phase II/III trials are already underway in the UK, Brazil and South Africa are expected to start soon in the U.S.